Rilonacept

Summary

Rilonacept is an engineered dimeric fusion protein consisting of the ligand-binding domains of IL-1 receptor (IL-1R) and IL-1 receptor accessory protein (IL-1RAcP) linked to human IgG1.Rilonacept blocks IL-1 beta signaling by acting as a decoy receptor that binds IL-1 beta.  

Rilonacept, approved by the FDA under Orphan Drug Status in February 2008, is the first approved biologic in the new class of therapeutics known as 'Cytokine Traps' . These 'traps' are engineered to exhibit much higher binding affinities to their targets than traditional decoy receptor constructs which possess only monomeric binding sites (e.g. anakinra).

Treatment of cryoprin-associated periodic fever syndromes (CAPS), including Muckle-Wells syndrome (MWS) and familial cold autoinflammatory syndrome (FCAS) in children 12 years and older are approved FDA indications.

Brand Name

Arcalyst

Other Names

IL-1 Trap, IL-1 Blocker

Molecular Target

IL-1 beta (IL-1β)

Molecular Structure

Dimeric fusion protein; ligand-binding domains of IL-1 receptor (IL-1R) & IL-1 receptor accessory protein (IL-1RAcP) linked to human IgG1

Licensed Indication, Major Target Diseases

cryopyrin-associated periodic fever syndromes (CAPS), including Muckle-Wells syndrome (MWS) and familial cold autinflammatory syndrome (FCAS) in children 12 years and older.

Manufacturer/Distributor

Regeneron

References